Aiming to bolster ivonescimab’s case ahead of a key FDA decision, Summit Therapeutics has provided
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Summit's ivonescimab cuts death risk 24% (HR 0.76) in Western NSCLC patients at the 2-year HARMONi mark, but median survival…
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
Summit Therapeutics shares updated Phase 3 data, revealing improving overall survival trends for lung cancer therapy ivonescimab.
